BioMarin Pharmaceutical (NASDAQ:BMRN) Announces Earnings Results, Beats Expectations By $0.25 EPS

BioMarin Pharmaceutical (NASDAQ:BMRN) issued its quarterly earnings results on Thursday. The biotechnology company reported $1.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.25, FiscalAI reports. BioMarin Pharmaceutical had a net margin of 8.29% and a return on equity of 6.50%. The firm had revenue of $989.71 million during the quarter, compared to analysts’ expectations of $932.03 million. During the same quarter in the prior year, the business earned $1.44 EPS. BioMarin Pharmaceutical’s quarterly revenue was up 20.0% compared to the same quarter last year. BioMarin Pharmaceutical updated its FY 2026 guidance to 4.900-5.100 EPS.

Here are the key takeaways from BioMarin Pharmaceutical’s conference call:

• Second-quarter revenue rose 20% year over year to nearly $1 billion, supported by broad-based demand and the Amicus contribution. BioMarin raised its full-year revenue, VOXZOGO revenue, and non-GAAP EPS guidance.
• The Amicus integration is progressing ahead of expectations, with projected peak revenue of $1.4 billion for GALAFOLD and $1.2 billion for POMBILITI/OPFOLDA, plus approximately $220 million in annual cost synergies by 2028. Management expects meaningful EPS accretion beginning in 2027 and deleveraging roughly one year earlier than previously anticipated.
• VOXZOGO revenue increased 14% year over year, while treated children grew more than 20% globally despite a new U.S. competitor. Approximately 90% of U.S. patients remained on therapy, and BioMarin submitted a supplemental application for hypochondroplasia approval, potentially supporting a 2027 launch.
• BioMarin added BMN 820, an oral CCR2 inhibitor in Phase III development for focal segmental glomerulosclerosis, to its late-stage pipeline. The company also expects to pursue additional clinical-stage business-development opportunities over the next 12 to 18 months.
• Acquisition financing is increasing annual interest expense by approximately $200 million, or $50 million per quarter, while reduced cash balances are lowering interest income. These factors, along with higher operating expenses, contributed to lower year-over-year non-GAAP diluted EPS in the quarter.

BioMarin Pharmaceutical Stock Performance

NASDAQ BMRN traded up $1.55 during trading hours on Thursday, hitting $61.46. 3,446,826 shares of the stock were exchanged, compared to its average volume of 1,585,874. The company has a quick ratio of 4.20, a current ratio of 5.81 and a debt-to-equity ratio of 0.23. The company has a market cap of $11.88 billion, a price-to-earnings ratio of 44.86, a price-to-earnings-growth ratio of 0.46 and a beta of 0.24. BioMarin Pharmaceutical has a 12-month low of $49.26 and a 12-month high of $66.28. The stock has a 50-day moving average of $58.06 and a 200 day moving average of $57.01.

Hedge Funds Weigh In On BioMarin Pharmaceutical

A number of large investors have recently modified their holdings of BMRN. Corient Private Wealth LLC grew its holdings in BioMarin Pharmaceutical by 159.5% during the fourth quarter. Corient Private Wealth LLC now owns 15,145 shares of the biotechnology company’s stock worth $900,000 after acquiring an additional 9,309 shares during the period. Mercer Global Advisors Inc. ADV lifted its holdings in BioMarin Pharmaceutical by 1.4% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 64,069 shares of the biotechnology company’s stock valued at $3,808,000 after acquiring an additional 910 shares during the period. EP Wealth Advisors LLC purchased a new stake in shares of BioMarin Pharmaceutical during the 4th quarter worth $240,000. Krensavage Asset Management LLC boosted its position in shares of BioMarin Pharmaceutical by 29.4% during the 4th quarter. Krensavage Asset Management LLC now owns 524,786 shares of the biotechnology company’s stock worth $31,188,000 after purchasing an additional 119,336 shares in the last quarter. Finally, Mackenzie Financial Corp grew its stake in shares of BioMarin Pharmaceutical by 114.0% during the 4th quarter. Mackenzie Financial Corp now owns 375,067 shares of the biotechnology company’s stock worth $22,082,000 after purchasing an additional 199,840 shares during the period. 98.71% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Canaccord Genuity Group reduced their target price on shares of BioMarin Pharmaceutical from $116.00 to $111.00 and set a “buy” rating for the company in a report on Friday, May 22nd. Morgan Stanley lowered their price target on BioMarin Pharmaceutical from $120.00 to $119.00 and set an “overweight” rating on the stock in a report on Tuesday, May 5th. Weiss Ratings upgraded BioMarin Pharmaceutical from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, June 26th. Bank of America reduced their price objective on BioMarin Pharmaceutical from $85.00 to $80.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Finally, Wall Street Zen downgraded BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, June 6th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.09.

Key Headlines Impacting BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Quarterly earnings and revenue beat estimates. BioMarin reported quarterly EPS of $1.20, above consensus estimates ranging from $0.94 to $0.96. Revenue rose 20% year over year to approximately $990 million, exceeding analysts’ expectations of about $932 million. BioMarin Pharmaceutical Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Full-year EPS guidance was raised above expectations. Management now expects fiscal 2026 EPS of $4.90-$5.10, compared with the consensus estimate of $4.80. The company also cited stronger growth expectations for revenue and VOXZOGO, supporting the improved outlook. BioMarin Reports Second Quarter 2026 Financial and Operating Results
• Positive Sentiment: New products could strengthen longer-term growth. BioMarin said the addition of GALAFOLD and POMBILITI plus OPFOLDA, together with expected cost synergies, should accelerate revenue growth, expand operating margins, increase cash flow and be accretive to non-GAAP EPS through the mid-2030s. BioMarin Reports Second Quarter 2026 Financial and Operating Results
• Neutral Sentiment: Revenue guidance was maintained broadly in line with consensus. Full-year revenue guidance of approximately $3.9 billion matched analysts’ expectations, so the principal upside came from the stronger-than-expected earnings outlook rather than a revenue forecast increase.
• Negative Sentiment: Reported EPS declined from the prior-year period. Quarterly EPS fell from $1.44 to $1.20, although the result still surpassed analyst estimates and revenue growth remained strong. BioMarin Q2 Earnings Snapshot

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.